BAL PHARMA EXTENDS ITS FOOTHOLD IN THE PHARMA MARKET
Speaking on the refurbishing of its marketing and distribution force, Mr. Deepak Sarda, Vice President, Marketing, Bal Pharma limited said “We have taken this strategic step to market aggressively in South India with a prime focus in Andhra Pradesh; one of India’s largest pharma market. The company has a strong establishment in other three states of South and feels this is a right time to look towards largest South market, especially when the company has won acknowledgement at the international level too. We are looking at an exponential growth taking the present AP market to 20 crores in the next 4 years. This step will also support our vision to be a 1000 crore company in the near future.”
Bal Pharma Limited has embarked on a greater expansion keeping in view of the ambitious vision plan of 1000 Cr by 2012.The total Indian Pharma market is estimated to be around 32409 Crores growing at the rate of 15 %. Andhra Pradesh contributes 9.5 % to total Indian Pharmaceutical Market. The pharmaceutical market in Andhra Pradesh is estimated to be 2900 Crores growing at the rate of 14 %. In A.P, the total market size of the therapeutic segments like Anti-Diabetes (OHA’s) is 130 Cr, Cardiology: 331 Cr, PPI: 130 Cr, Antihistamines: 51 Cr, Gynecology (Nutraceuticals like Calcium & Iron Preparations): 94 Cr, & Antibiotics groups like Macrolide 44 Cr,. Currently, Bal Pharma represents in these therapeutic segments of A.P market with its well established brands like Aziwin ,Diabend-M, Lipofix and new introductions, added Mr. Sarda.
Recently, Bal Pharma has already introduced few promising molecules like TELONG (Telmisartan 20, 40 & Telmisartan-H) for Hypertension, RABIFIX (Rabeprazole 20 mg &
Rabeprazole 20 mg with Domperidone 30 mg) PPI, GLYVOG (Voglibose 0.2 & 0.3 mg) for Diabetes & AZIWIN-AX (Azithromycin with Ambroxol) for Respiratory infections. Bal
Pharma plans to launch many molecules in various therapeutic segments like Cephalosporin’s, Anti-Arthritis, Nutraceuticals, Anti Hypertensives, Anti-Diabetes (OHA’s), Anti-Allergics & New Lipid lowering Agents, on all India basis which will boost up the net sales of Bal Pharma in the months to come.
Going ahead, the company is planning to file more DMFs in next few months, and this would comprise of a basket of products being required by the market as the country has an advanced healthcare system and demand for all types of pharmaceuticals is high. The company would be entering 15 new countries within the next financial year. With manpower of more than 1000 in the company, the company is committed to develop, manufacture and market innovative Pharma products. The company with its international quality systems, excellent infrastructure and outstanding manpower skills is working aggressively to become a reckoning name in the Indian & Global Pharmaceutical industry.
MORE ABOUT BAL PHARMA
Bal Pharma Ltd, a pharmaceutical company listed at Bombay Stock Exchange & National Stock Exchange is a leading manufacturer, marketer and exporter of pharmaceutical products in India and abroad. Established in 1993, the company has an envious track record of providing its immaculate services in the health care market. The company’s strength spans a range of Branded formulations, APIs, Generics including Parentereals, and Intermediates, to Herbals. Bal Pharma has three manufacturing units, one for APIs coupled with R & D, the second for formulations both located at Bangalore and a third unit for Parentereals at Pune; all equipped with ultramodern state-of-the-art technology. All units conform to the GMP standards as laid down by WHO. Bal Pharma is also one of the top companies in the country having the latest Form Fill and Seal (FFS) technology.
K2 Communications Pvt.Ltd.
#96, 2nd Main Road, MLA Layout, R.T. Nagar, Bangalore - 560032
Tel: 91 80 23337344, Telefax: 080 - 23549354
K2 Communications Pvt Ltd, into its fifth year now, has achieved much success for itself and its clients.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BAL PHARMA EXTENDS ITS FOOTHOLD IN THE PHARMA MARKET here
News-ID: 49560 • Views: 1792
More Releases for Pharma
Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Erythrocyte Catalase Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Erythrocyte Catalase Market" across the global, regional and country level. The report provides 360° analysis of "Erythrocyte Catalase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Erythrocyte Catalase industry, and estimates the future trend of Erythrocyte Catalase market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business